glp 1 microdosing patch How to Wear GLP-1 Patches: Current Status and Approved Alternatives Can Microdosing GLP 1 Enhance
Description
The SURMOUNT-5 trial found approximately 20.2% average body-weight loss with branded tirzepatide versus 13.7% with branded semaglutide over 72 weeks in adults with obesity and without diabetes
This leads to steadier energy levels and better metabolic stability (NIH)
Recent evidence suggests that GLP-1RAs may exert direct renoprotective effects independent of their metabolic benefits
doi:10.2147/ceg.s303688
The role of GLP-1 receptor agonists in the treatment of obesity and type 2 diabetes mellitus
